Dr. Barry Schechter MD

Director of Cornea and External Disease, FLORIDA EYE MICROSURGICAL INSTITUTE INC

GLG News by Dr. Barry Schechter MD, Director of Cornea and External Disease

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Bausch makes foray into presbyopic arena

January 29, 2008

Analysis of:Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com

With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.

Newly identified risks for refractive surgery

April 16, 2007

Analysis of:Researchers report 13 cases of MRSA keratitis after laser refractive surgery | www.osnsupersite.com

Refractive surgery is taken for granted by patients to "get rid of their glasses and contact lenses". They rarely consider the possibility of loss of vision.

ISTA takes the lead in topical NSAID therapy

February 14, 2007

Analysis of:ISTA Pharmaceuticals Announces Positive Preliminary Xibrom Once-daily Formulation Clinical Results From U.S. Phase III Trials | pharmalive.com

There has been a sea change in the treatment of postoperative cataract patients. The addition of a nonsteroidal has significantly reduced postoperative complications such as edema, discomfort and inflammation.

Compliance with all medications is always an issue, and the use of a once daily medication potentially makes this a non-issue. I have been impressed with the BID Xibrom and my patients in the phase 3 trial did exceptionally well.

I expect that this will be well received, pending acceptance of formularies.

Additional Thoughts on Fusarium

May 10, 2006

Analysis of:Doubt Cast on Early Theory on Eye Infections | www.nytimes.com

Multiple species of Fusarium have been reported as pathogens.

ReStor gradually becoming more popular

May 10, 2006

Analysis of:Alcon Still Not Living Up to Valuation | www.fool.com

Dr Packer writes that the ReStor lens is taking time to catch on with cataract surgeons.

Page : 11 to 5 of 5

Subscribe to Updates

By RSS